Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

J&J Expands Russian OTC Foothold Via J.B. Chemicals Portfolio Acquisition

This article was originally published in PharmAsia News

Executive Summary

Johnson & Johnson expands its consumer health presence in Russia and other Eastern European markets with the acquisition of several OTC brands from J.B. Chemicals & Pharmaceuticals

You may also be interested in...



Emerging Views On Emerging Markets: Credit Suisse Healthcare Conference

PharmAsia News takes a closer look at presentations by Baxter, Forest, J&J, Novartis and Zimmer.

J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag

J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.

J&J And India’s J.B. Chemicals On Collision Course As Sale Of Russian OTC Business Hits Snag

J&J’s sudden claim for funds from an escrow account has sparked speculation on the future of the deal with J.B. Chemicals.

Table

View full table

Related Content

HBW Insight
Scrip
Scrip
Scrip
Scrip
Pink Sheet
Tags:
Latest Headlines

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

Sanofi Skates To Where The Puck Is With Immunology

Pipeline Watch: Five Approvals And 23 Phase III Updates

Metsera Launches As New Obesity Contender Flush With $290m

See All
UsernamePublicRestriction

Register

SC078088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By